全球胃扭轉治療市場規模、份額和趨勢分析報告－產業概況和2032年預測

胃扭轉治療市場規模

• 2024 年全球胃扭轉治療市場規模為282.3 億美元 ，預計 到 2032 年將達到 404.5 億美元，預測期內 複合年增長率為 4.6%。
• 市場成長主要得益於人們對胃扭轉作為一種嚴重胃腸道疾病的認識不斷提高，以及微創手術技術和治療方案的進步
• 此外，無論是住院還是門診，對早期診斷、有效幹預方法以及一體化護理路徑的需求日益增長，使得晚期胃扭轉治療方案成為醫療服務提供者的首選。這些因素正在加速創新治療方法的採用，從而顯著促進該行業的成長。

胃扭轉治療市場分析

• 胃扭轉治療是指透過醫療和外科幹預手段糾正胃部異常扭轉（扭轉）並防止其復發。治療的主要目標是緩解梗阻，恢復胃部正常血流，並預防缺血、壞死和穿孔等併發症。
• 對先進治療方案的需求不斷增長，主要原因是診斷率的提高、對胃扭轉併發症的認識的提高以及微創手術的技術進步
• 北美在胃扭轉治療市場佔據主導地位，2024 年其收入份額最大，為 43.6%，其特點是醫療支出高、醫療基礎設施先進，以及擁有大量提供創新外科和內視鏡解決方案的關鍵參與者
• 由於醫療基礎設施建設不斷加強、認知度不斷提高以及中國和印度等國家的患者人數不斷增加，預計亞太地區將成為預測期內胃扭轉治療市場增長最快的地區
• 手術領域在胃扭轉治療市場中佔據主導地位，2024 年的市場份額將達到 79.8%，這得益於其高成功率和醫療保健提供者對明確治療急性和慢性病例的偏好，以及微創腹腔鏡技術的日益普及

報告範圍和胃扭轉治療市場細分      

胃扭轉治療市場趨勢

“技術進步增強治療和病人護理”

• 全球胃扭轉治療市場的一個重要且正在加速發展的趨勢是整合先進技術，以增強患者護理、監測和治療管理。人工智慧驅動的診斷工具和語音啟動的醫療保健應用程式正在提高治療的精確度和患者的便利性。
  • For instance, AI-powered diagnostic platforms are being used to detect gastric volvulus symptoms earlier and more accurately, while voice-enabled apps assist patients in managing their treatment schedules and post-operative care instructions. Similarly, telemedicine solutions incorporating voice recognition help streamline consultations and follow-ups for gastric volvulus patients
• AI integration enables predictive analytics that can assess patient risk factors and suggest personalized treatment plans, improving clinical outcomes. Voice control features support hands-free patient interaction with healthcare systems, facilitating ease of use, especially for elderly or mobility-impaired individuals
• The seamless integration of these technologies with electronic health records (EHR) and smart medical devices allows centralized monitoring and management of gastric volvulus cases, enhancing coordination between patients, caregivers, and healthcare providers
• This move towards intelligent, patient-centric treatment solutions is reshaping expectations in gastric volvulus care. As a result, companies and healthcare providers are investing in AI-enabled diagnostic tools and voice-integrated patient support systems to offer improved treatment experiences
• The demand for technologically advanced gastric volvulus treatment solutions is rapidly growing across hospitals, specialty clinics, and homecare settings, driven by the increasing focus on personalized medicine and remote patient management

Gastric Volvulus Treatment Market Dynamics

Driver

“Growing Need Due to Rising Prevalence and Advancements in Diagnostic Techniques”

• The rising incidence of gastric volvulus, particularly among geriatric populations and patients with underlying anatomical abnormalities, is driving demand for prompt and effective treatment options
  • For instance, in March 2024, the Mayo Clinic launched a study aimed at improving early diagnosis of gastric volvulus using high-resolution imaging, signaling increased clinical focus on this condition. Such initiatives support the growth of the gastric volvulus treatment market during the forecast period
• As awareness increases among clinicians and patients about the critical nature of early intervention, there is a growing emphasis on faster diagnosis and minimally invasive surgical solutions to reduce complications and hospital stay durations
• Furthermore, advancements in radiologic imaging, such as CT and MRI, have significantly enhanced the detection rate of gastric volvulus, allowing for quicker treatment decisions and better patient outcomes
• The integration of diagnostic tools into emergency and gastroenterology departments, coupled with growing healthcare infrastructure in emerging markets, is also contributing to increased treatment access. These developments support the expanding adoption of surgical and non-surgical interventions in both developed and developing healthcare settings

Restraint/Challenge

“Limited Awareness and High Risk of Misdiagnosis”

• One of the major challenges facing the gastric volvulus treatment market is the limited awareness of the condition among both patients and healthcare providers, particularly in rural and underdeveloped areas. The rarity and nonspecific symptoms of gastric volvulus often lead to misdiagnosis or delayed diagnosis
  • For instance, studies published in 2023 by the Journal of Gastrointestinal Surgery reported that misdiagnosis remains a leading contributor to complications such as gastric necrosis and volvulus recurrence
• Due to a lack of training or exposure, primary care physicians and emergency medical staff may fail to identify gastric volvulus promptly, leading to increased patient morbidity and longer hospital stays
• Moreover, advanced imaging techniques needed for accurate diagnosis may not be readily available in low-resource settings, which limits early intervention opportunities. The technical expertise required for surgical intervention, particularly laparoscopic procedures, further compounds access challenges in some regions
• Addressing these issues through increased clinical training, awareness campaigns, and investment in diagnostic infrastructure will be critical to improving detection and treatment outcomes and thereby supporting long-term market growth

Gastric Volvulus Treatment Market Scope

The market is segmented on the basis of type, treatment type, drug class, route of administration, end-user, and distribution channel.

• By Type

On the basis of type, the gastric volvulus treatment market is segmented into organo-axial volvulus and mesentero-axial volvulus. The organo-axial volvulus segment dominated the market with the largest revenue share of 61.3% in 2024, attributed to its higher prevalence, especially in elderly patients and those with diaphragmatic defects. This type is more frequently diagnosed in clinical settings and often requires surgical intervention due to its recurrent nature.

The mesentero-axial volvulus segment is projected to witness the fastest CAGR of 7.8% during the forecast period, driven by growing awareness, advancements in imaging techniques, and the increasing accuracy of diagnosis among healthcare professionals.

• By Treatment Type

On the basis of treatment type, the gastric volvulus treatment market is segmented into medication and surgery. The surgery segment accounted for the largest revenue share of 79.8% in 2024, owing to its definitive treatment approach for both acute and chronic gastric volvulus cases. Minimally invasive laparoscopic procedures are gaining preference due to shorter hospital stays and faster recovery times.

The medication segment is expected to witness the fastest CAGR from 2025 to 2032, primarily for non-emergency management and as adjunct therapy to reduce symptoms such as nausea and abdominal pain.

• By Drug Class

On the basis of drug class, the gastric volvulus treatment market is segmented into analgesics, antiemetic agents, and others. The antiemetic agents segment held the largest share of 48.9% in 2024, due to their widespread use in managing nausea and vomiting, which are primary symptoms of gastric volvulus.

The analgesics segment is projected to grow at a significant CAGR of 6.3% from 2025 to 2032, driven by the need for pain relief in both preoperative and postoperative care.

• By Route of Administration

On the basis of route of administration, the gastric volvulus treatment market is segmented into oral and parenteral. The parenteral segment dominated the market with a revenue share of 57.6% in 2024, as intravenous administration is preferred in emergency care settings for rapid drug action.

The oral segment is expected to witness the fastest CAGR from 2025 to 2032 due to its use in outpatient settings and for patients in stable condition or under symptom management plans.

• By End-User

On the basis of end-user, the market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment held the largest market share of 66.5% in 2024, due to the availability of surgical equipment, emergency services, and specialized care required for managing acute gastric volvulus cases.

The homecare segment is expected to witness the fastest growth at a CAGR of 8.1%, fueled by post-surgical care, ongoing symptom management, and increased preference for home-based recovery supported by healthcare professionals.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy and retail pharmacy. The hospital pharmacy segment held the largest market share of 63.7% in 2024, supported by direct in-hospital treatment and the immediate need for medications and surgical tools in emergency settings.

The retail pharmacy segment is projected to grow at a notable CAGR from 2025 to 2032, driven by rising patient discharges and follow-up treatments requiring medication from external sources, especially antiemetics and pain relievers.

Gastric Volvulus Treatment Market Regional Analysis

• North America dominates the gastric volvulus treatment market with the largest revenue share of 43.6% in 2024, driven by the region's advanced healthcare infrastructure, higher awareness of gastrointestinal disorders, and greater accessibility to diagnostic imaging and surgical interventions
• Patients and healthcare providers in the region prioritize timely diagnosis and treatment of gastric volvulus, supported by strong clinical guidelines and the availability of minimally invasive surgical procedures in both public and private healthcare settings
• 醫療保健支出增加、老齡人口更容易患胃動力障礙，以及越來越重視透過早期幹預和先進的治療方案改善患者預後，進一步鞏固了這一區域主導地位

美國胃扭轉治療市場洞察

2024年，美國胃扭轉治療市場佔據北美地區最大收入份額，這得益於先進的診斷能力、廣泛的緊急外科手術資源以及患者和醫護人員的高度認知。領先的胃腸外科醫生和專科醫院的存在，以及胃腸疾病病例的不斷增加，繼續支撐著強勁的市場需求。

歐洲胃扭轉治療市場洞察

在2025年至2032年期間，歐洲胃扭轉治療市場的複合年增長率將達到7.9%，這得益於老齡人口增長、急診服務可及性的改善以及醫療基礎設施的不斷擴展。在德國、英國和法國等國家，腹腔鏡手術和早期診斷幹預措施的應用日益廣泛。嚴格的臨床方案和不斷增長的醫療資金也在推動市場擴張方面發揮關鍵作用。

英國胃扭轉治療市場洞察

英國胃扭轉治療市場預計在預測期內將以6.8%的複合年增長率增長，這得益於微創手術需求的不斷增長以及與年齡相關的胃病負擔的不斷加重。日益增多的公私合作夥伴關係以及英國國家醫療服務體系（NHS）為減少急診延誤而做出的努力，正在提高早期診斷和及時手術幹預的比率。

德國胃扭轉治療市場洞察

預計德國胃扭轉治療市場將以7.2%的複合年增長率成長，這得益於先進醫療技術的普及以及機構對胃腸道護理的高度重視。德國對訓練、臨床試驗和內視鏡手術的重視，有助於提高治療成功率和病患預後，進而進一步提升市場信譽。

亞太胃扭轉治療市場洞察

受醫療支出增長、城鎮化進程加快以及人們對胃腸道疾病認識不斷提高的推動，亞太地區胃扭轉治療市場預計在2025年至2032年間以19.4%的複合年增長率快速增長。該地區各國政府正在擴大醫療覆蓋面，並投資建造內視鏡和外科手術基礎設施，使城鄉地區都能更方便地獲得治療。

中國胃扭轉治療市場洞察

2024年，中國胃扭轉治療市場佔據亞太地區最大收入份額，這得益於消化系統疾病和運動功能障礙病例的增加、城市人口密度的提高以及三級醫院就診機會的改善。本土製造能力的提升以及政府對手術設備和急救護理的支持，正在推動國內胃扭轉治療方案的普及和採用。

日本胃扭轉治療市場洞察

日本胃扭轉治療市場正穩定成長，這得益於該國人口老化、醫療素養高以及對技術創新的重視。內視鏡診斷的廣泛應用以及對微創手術技術的強勁需求，也使該市場受益匪淺。醫院對機器人技術和先進手術平台的投資不斷增加，也有助於改善病患治療效果並提高手術效率。

胃扭轉治療市場份額

胃扭轉治療產業主要由知名公司主導，包括：

• 澤井製藥株式會社（日本）
• PAI Pharma（美國）
• 太陽製藥工業有限公司（印度）
• ANI Pharmaceuticals, Inc.（美國）
• Fresenius SE & Co. KGaA（德國）
• 梅恩製藥集團有限公司（澳洲）
• 梯瓦製藥工業股份有限公司（以色列）
• 格蘭馬克製藥有限公司（印度）
• Tris Pharma, Inc.（美國）
• 輝瑞公司（美國）
• Mallinckrodt（英國）
• Viatris Inc.（美國）
• 葛蘭素史克公司（英國）  
• Vintage Labs（印度）
• Zydus集團（印度）

SKU-46429